BioWorld Asia

April 30, 2003

Diatos Licenses European Rights To Cancer Drug From Medarex

PARIS - Diatos SA and Medarex Inc. signed a licensing agreement giving Diatos exclusive European rights to develop and commercialize a potential new cancer treatment. (BioWorld International) Read More

Biotech Groups In Norway Unite, Plan To Catch Up With Neighbors

Genetic Study Of Clotting Enzyme Points To 'Fantastic' Drug Target

Curnock Cook Investing Again After Forming New €150M Fund

No Abstract Read More

PPL Gives Up Plans On Plant To Manufacture AAT Product

French Companies, Agency Unite For Effort In America

Alizyme Eyes Phase III, Alliance Following Renzapride Results

GenoWay Raises EUR3.3M To Fund Work On Animal, In Vitro Models

Merck Stops Development Of Celltech PDE-4 Inhibitor

UK Industry Gathers To Celebrate 50th Anniversary Of DNA Finding

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 8, 2026.

ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins

BioWorld

If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...

New York University identifies new analogues of mannose-6-phosphate

BioWorld Science

New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

Woman taking medication for mental illness

Autobahn on the fast track with bipolar thyroid agonist

BioWorld

Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...